TOP 5 Price Targets by Analysts on 18.09.25
Reading Time: 4 minutes
Aquestive Therapeutics [US03843E1047] H.C. Wainwright reaffirms Buy rating with a price target of $10 (107% upside potential) The positive assessment is based on the company's solid financial position as well as progress in clinical development, particularly regarding the drug Anaphylm . This is a novel sublingual delivery form for the treatment of anaphylaxis, intended to provide a non-invasive alternative to traditional epinephrine injectors. The market launch is planned for spring 2026, with the FDA setting the PDUFA date for January...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
